University of the Sunshine Coast Clinical Trial Centre
Welcome,         Profile    Billing    Logout  
 1 Trial 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Scott, Robert M
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
ITV2002, NCT05604690: Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers

Completed
1
40
RoW
Avacc 10, Outer Membrane Vesicles (OMV) : OMV alone in vehicle, Placebo
Intravacc B.V., Novotech (Australia) Pty Limited
COVID-19
08/23
01/24
NCT06556147: A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults

Active, not recruiting
1
144
RoW
VXB-241 60 mcg (Low Dose), VXB-241 120 mcg (Medium Dose), VXB-241 240 mcg (Medium-high Dose), VXB-241 480 mcg (High Dose), VXB-241, Placebo, Arexvy 120 mcg
Vicebio Australia Proprietary Limited
Healthy Volunteers
08/25
05/27
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

Active, not recruiting
N/A
525
US
Investigational LUX-Dx ICM Implant
Boston Scientific Corporation
Heart Failure
05/26
06/26
Poechhacker, Susan
NCT04674683 / 2019-002521-30: Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Active, not recruiting
3
450
Europe, Japan, US, RoW
HBI-8000 in combination with nivolumab, For HBI-8000: tudicdinostat; For nivolumab: OPDIVO®, Placebo in combination with nivolumab, For nivolumab: OPDIVO®
HUYABIO International, LLC., Bristol-Myers Squibb
Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
12/24
10/25
NCT04735575: A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

Recruiting
1/2
66
RoW
EMB-06
Shanghai EpimAb Biotherapeutics Co., Ltd.
Relapsed or Refractory Multiple Myeloma
12/23
03/25
Thackwray, Susan
ACTRN12620001103954: A Seamless Phase 1b Study to Evaluate Safety, Tolerability and Efficacy of SER-301 in Adult Subjects with Active Mild-to-Moderate Ulcerative Colitis (Part 2)

Withdrawn
1
50
 
PSI CRO Australia Pty. Ltd., Seres Therapeutics, Inc.
Ulcerative Colitis
 
 
ACTRN12620000963921: A Seamless Phase 1b Study to Evaluate Safety, Tolerability and Efficacy of SER-301 in Adult Subjects with Active Mild-to-Moderate Ulcerative Colitis (Part 1)

Completed
1
15
 
PSI CRO Australia Pty. Ltd., Seres Therapeutics, Inc.
Ulcerative Colitis
 
 

Download Options